Search Within

Melanoma Disease Management Team

Formats
  1. Journal Article (1604)
  2. Meeting Abstract (791)
  3. Book Section (104)
  4. Review (72)
  5. Editorial (58)
  6. Research Letter (45)
  7. Guidelines (26)
  8. Conference Paper (22)
  9. Correspondence (21)
  10. Miscellaneous (16)
  11. Book Whole (11)
Groups
  1. Department of Medicine (1690)
  2. Survivorship Research (1193)
  3. Solid Tumor Oncology Division (1052)
  4. Department of Pathology and Laboratory Medicine (957)
  5. Surgery (947)
  6. Melanoma and Immunotherapeutics Service (793)

More Groups

People
  1. Klaus Busam (698)
  2. Daniel Coit (543)
  3. Allan Halpern (401)
  4. Michael Postow (369)
  5. Alexander Shoushtari (247)
  6. Jedd Wolchok (222)

More People

Years
  1. 2025 (89)
  2. 2024 (138)
  3. 2023 (160)
  4. 2022 (167)
  5. 2021 (149)
  6. 2020 (142)

More Years

Publications
  1. Journal of Clinical Oncology (269)
  2. Annals of Surgical Oncology (221)
  3. Journal of the American Academy of Dermatology (123)
  4. Journal of Investigative Dermatology (84)
  5. Modern Pathology (67)
  6. American Journal of Surgical Pathology (64)

More Publications

Publishers
  1. Springer (341)
  2. American Society of Clinical Oncology (284)
  3. Elsevier Inc. (231)
  4. Lippincott Williams & Wilkins (229)
  5. Wiley Blackwell (162)
  6. Elsevier Science, Inc. (160)

More Publishers

Results (2770)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)
    Meeting Abstract

    Carvajal, R. D.; Sato, T.; Butler, M. O.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Rioth, M.; Hamid, O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival benefit from tebentafusp in patients with best response of progressive disease
    Meeting Abstract

    Joshua, A. M.; Baurain, J. F.; Piperno-Neumann, S.; Nathan, P.; Hassel, J. C.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)
    Meeting Abstract

    Sato, T.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Nathan, P.; Rioth, M.; Hamid, O.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma
    Meeting Abstract

    Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM)
    Meeting Abstract

    Bai, X.; Shoushtari, A. N.; Warner, A. B.; Quach, H.; Cann, C. G.; Zhang, M.; Pallan, L.; Harvey, C.; Si, L.; Tang, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma
    Meeting Abstract

    Orloff, M.; Carvajal, R. D.; Shoushtari, A. N.; Sacco, J. J.; Schlaak, M.; Watkins, C.; Abdullah, S. E.; Goodall, H.; Butler, M. O.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI)
    Meeting Abstract

    Grimes, J.; Shoushtari, A. N.; Orloff, M.; Khan, S.; Chiuzan, C.; Hsiao, S. J.; McDonnell, D.; Marr, B. P.; Carvajal, R. D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis
    Meeting Abstract

    Weber, J. S.; Poretta, T.; Stwalley, B.; Sakkal, L.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma
    Meeting Abstract

    Jameson-Lee, M.; Ott, P. A.; Luke, J. J.; Postow, M. A.; Poklepovic, A. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma
    Meeting Abstract

    Amaria, R. N.; Postow, M. A.; Tetzlaff, M. T.; Ross, M. I.; Glitza, I. C.; McQuade, J. L.; Wong, M. K. K.; Gershenwald, J. E.; Goepfert, R.; Keung, E. Z. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save